ImmunoForge, a biopharmaceutical company focused on rare diseases, announced that its leaders will be in San Francisco for the 43rd Annual J.P. Morgan Healthcare Conference from January 12-15, 2026. They will have private one-on-one meetings with global pharmaceutical companies and investors.
Instead of giving a formal presentation, ImmunoForge will focus on private meetings to discuss the progress of their key treatments and partnerships. The company is looking for partners to help lead clinical trials in the U.S. for its Phase 2 treatments.
Key points for partnering include:
- ELP (Elastin-Like Polypeptide) platform: This allows for peptide and protein combinations, and can be used for monthly treatments.
- BBB penetrating ELP platform: A system that can create monthly treatments for the brain and central nervous system.
- PF1801 (for Polymyositis/Dermatomyositis, DMD & Sarcopenia): This treatment is in Phase 2 trials in South Korea, and U.S. FDA approval for Phase 2 is already granted, making it ready for U.S. trials with a global partner.
- PF1804 (for DMD Cardiomyopathy): Another treatment with FDA Phase 2 approval, ready for clinical trials.
- PF1807 (for Sarcopenia): A monthly treatment for muscle loss, focused on preventing and treating related diseases.
- KF1601 (for CML): Licensed for Phase 1 trials in Korea, with global rights available for international partners.
Executive Statement
According to a representative from ImmunoForge, their goal for JPM 2026 week is to meet with potential partners who can leverage our FDA-cleared INDs to rapidly bring these therapies to the U.S. market. As a lean biotech, they have focused on de-risking their assets through regulatory clearances; they are now looking for the right global collaborators to take these programs through the next phase of clinical development and to the commercial markets. In addition to licensing deals with global pharmaceutical companies, they are also actively willing to pursue NewCo models led by investors. They intend to expand their development capabilities by introducing their diverse pipeline to global companies, including their established long-acting ELP platform and the newly developed BBB-penetrating ELP platform technology.
